|
|
Blood, 15 September 2005, Vol. 106, No. 6, pp. 2162-2168.
Prepublished online as a Blood First Edition Paper on May 26, 2005; DOI 10.1182/blood-2005-03-1320.
Previous Article | Next Article 
Submitted March 31, 2005
Accepted May 16, 2005
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
Amy V Jones, Sebastian Kreil, Katerina Zoi, Katherine Waghorn, Claire Curtis, Lingyan Zhang, Joannah Score, Rachel Seear, Andrew J Chase, Francis H Grand, Helen White, Christine Zoi, Dimitris Loukopoulos, Evangelos Terpos, Elisavet-Christine Vervessou, Beate Schultheis, Michael Emig, Thomas Ernst, Eva Lengfelder, Rudiger Hehlmann, Andreas Hochhaus, David Oscier, Richard T Silver, Andreas Reiter, and Nicholas C Cross*
Wessex Regional Genetics Laboratory, UK and Human Genetics Division, University of Southampton, Salisbury, United Kingdom
Foundation of Biomedical Research of Academy of Athens, Athens, Greece
General Airforce Hospital, Athens, Greece
"Errikos Dynan" Athens General Hospital, Athens, Greece
III. Medizinische Universitatsklinik, Fakultat fur Klinische Medizin Mannheim der Universitat Heidelberg, Mannheim, Germany
Royal Bournemouth Hospital, Bournemouth, United Kingdom
Weill Medical College of Cornell University, New York, NY, USA
* Corresponding author; email: ncpc{at}soton.ac.uk.
The analysis of rare chromosomal translocations in myeloproliferative disorders has highlighted the importance of aberrant tyrosine kinase signalling in the pathogenesis of these diseases. Here we have investigated samples from 679 patients and controls for the non-receptor tyrosine kinase JAK2 V617F mutation. Of the 480 MPD samples, the proportion of positive cases per disease subtype was atypical or unclassified MPD 30/152 (20%), idiopathic hypereosinophilic syndrome 2/134 (2%), polycythemia vera 58/72 (81%), essential thrombocythemia 24/59 (41%) and idiopathic myelofibrosis 15/35 (43%). V617F was not identified in patients with systemic mastocytosis (n=28), chronic or acute myeloid leukemia (n=35), secondary erythrocytosis (n=4) or normal controls (n=160). Homozygosity for V617F was seen in 43% of mutant samples and closely correlated with chromosome 9p uniparental disomy. Homozygosity was significantly less common in ET compared to other MPD subtypes. In 53 cases analysed, the median level of PRV1 expression was significantly higher in V617F positive cases compared to cases without the mutation. We conclude that V617F is widespread in MPDs. Detection of this acquired mutation is likely to have a major impact on the way MPD patients are diagnosed, as well as serving as an obvious target for signal transduction therapy.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
Related Letters in Blood Online:
-
A sensitive high-throughput method to detect activating mutations of Jak2 in peripheral-blood samples
- Martin Sattler, Christoph Walz, Brian J. Crowley, Eva Lengfelder, Pasi A. Jänne, Andrew M. Rogers, Yanan Kuang, Robert J. Distel, Andreas Reiter, and James D. Griffin
Blood 2006 107: 1237-1238.
[Full Text]
[PDF]
-
Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7
- Stefan Fröhling, Daniel B. Lipka, Sabine Kayser, Claudia Scholl, Richard F. Schlenk, Hartmut Döhner, D. Gary Gilliland, Ross L. Levine, and Konstanze Döhner
Blood 2006 107: 1242-1243.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
A. Quintas-Cardama, H. Kantarjian, T. Manshouri, R. Luthra, Z. Estrov, S. Pierce, M. A. Richie, G. Borthakur, M. Konopleva, J. Cortes, et al.
Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera
J. Clin. Oncol.,
November 10, 2009;
27(32):
5418 - 5424.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Cankovic, L. Whiteley, R. C. Hawley, R. J. Zarbo, and D. Chitale
Clinical Performance of JAK2 V617F Mutation Detection Assays in a Molecular Diagnostics Laboratory: Evaluation of Screening and Quantitation Methods
Am J Clin Pathol,
November 1, 2009;
132(5):
713 - 721.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. W. Vardiman, J. Thiele, D. A. Arber, R. D. Brunning, M. J. Borowitz, A. Porwit, N. L. Harris, M. M. Le Beau, E. Hellstrom-Lindberg, A. Tefferi, et al.
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
Blood,
July 30, 2009;
114(5):
937 - 951.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. H. Grand, C. E. Hidalgo-Curtis, T. Ernst, K. Zoi, C. Zoi, C. McGuire, S. Kreil, A. Jones, J. Score, G. Metzgeroth, et al.
Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms
Blood,
June 11, 2009;
113(24):
6182 - 6192.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. A. Gustafson, P. Lin, S. S. Chen, L. Chen, L. V. Abruzzo, R. Luthra, L. J. Medeiros, and S. A. Wang
Therapy-Related Acute Myeloid Leukemia With t(8;21) (q22;q22) Shares Many Features With De Novo Acute Myeloid Leukemia With t(8;21)(q22;q22) but Does Not Have a Favorable Outcome
Am J Clin Pathol,
May 1, 2009;
131(5):
647 - 655.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Rapado, S. Grande, E. Albizua, R. Ayala, J.-A. Hernandez, M. Gallardo, F. Gilsanz, and J. Martinez-Lopez
High Resolution Melting Analysis for JAK2 Exon 14 and Exon 12 Mutations: A Diagnostic Tool for Myeloproliferative Neoplasms
J. Mol. Diagn.,
March 1, 2009;
11(2):
155 - 161.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Andrikovics, N. Meggyesi, A. Szilvasi, J. Tamaska, G. Halm, S. Lueff, S. Nahajevszky, M. Egyed, J. Varkonyi, G. Mikala, et al.
HFE C282Y Mutation as a Genetic Modifier Influencing Disease Susceptibility for Chronic Myeloproliferative Disease
Cancer Epidemiol. Biomarkers Prev.,
March 1, 2009;
18(3):
929 - 934.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Verstovsek
New Therapeutic Options for Myelofibrosis
ASCO Educational Book,
January 1, 2009;
2009(1):
426 - 429.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Zhao, G. A. Follows, P. A. Beer, L. M. Scott, B. J.P. Huntly, A. R. Green, and D. R. Alexander
Inhibition of the Bcl-xL Deamidation Pathway in Myeloproliferative Disorders
N. Engl. J. Med.,
December 25, 2008;
359(26):
2778 - 2789.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. L. Spivak and R. T. Silver
The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal
Blood,
July 15, 2008;
112(2):
231 - 239.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Xing, T. H. Wanting, W. Zhao, J. Ma, S. Wang, X. Xu, Q. Li, X. Fu, M. Xu, and Z. J. Zhao
Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice
Blood,
May 15, 2008;
111(10):
5109 - 5117.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Xiang, Y. Zhao, V. Mitaksov, D. H. Fremont, Y. Kasai, A. Molitoris, R. E. Ries, T. L. Miner, M. D. McLellan, J. F. DiPersio, et al.
Identification of somatic JAK1 mutations in patients with acute myeloid leukemia
Blood,
May 1, 2008;
111(9):
4809 - 4812.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. M. Mannucci and F. Peyvandi
Thrombophilia Screening: Little Role for the JAK2V617F Mutation
Mayo Clin. Proc.,
April 1, 2008;
83(4):
398 - 399.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Wernig, J. R. Gonneville, B. J. Crowley, M. S. Rodrigues, M. M. Reddy, H. E. Hudon, C. Walz, A. Reiter, K. Podar, Y. Royer, et al.
The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes
Blood,
April 1, 2008;
111(7):
3751 - 3759.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. P. Steensma and A. Tefferi
JAK2 V617F and ringed sideroblasts: not necessarily RARS-T
Blood,
February 1, 2008;
111(3):
1748 - 1748.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Pietra, S. Li, A. Brisci, F. Passamonti, E. Rumi, A. Theocharides, M. Ferrari, H. Gisslinger, R. Kralovics, L. Cremonesi, et al.
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders
Blood,
February 1, 2008;
111(3):
1686 - 1689.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. James
The JAK2V617F Mutation in Polycythemia Vera and Other Myeloproliferative Disorders: One Mutation for Three Diseases?
Hematology,
January 1, 2008;
2008(1):
69 - 75.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. L. Levine and M. Heaney
New Advances in the Pathogenesis and Therapy of Essential Thrombocythemia
Hematology,
January 1, 2008;
2008(1):
76 - 82.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. W. Vardiman
Integration of Histology and Genetics in the Diagnosis and Classification of Myeloproliferative Neoplasms
ASCO Educational Book,
January 1, 2008;
2008(1):
339 - 345.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. Percy, L. M. Scott, W. N. Erber, C. N. Harrison, J. T. Reilly, F. G.C. Jones, A. R. Green, and M. F. McMullin
The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels
Haematologica,
December 1, 2007;
92(12):
1607 - 1614.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Pradhan, Q. T. Lambert, and G. W. Reuther
Transformation of hematopoietic cells and activation of JAK2-V617F by IL-27R, a component of a heterodimeric type I cytokine receptor
PNAS,
November 20, 2007;
104(47):
18502 - 18507.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Chaligne, C. James, C. Tonetti, R. Besancenot, J. P. Le Couedic, F. Fava, F. Mazurier, I. Godin, K. Maloum, F. Larbret, et al.
Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis
Blood,
November 15, 2007;
110(10):
3735 - 3743.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Helbig, B. Stella-Holowiecka, M. Majewski, M. Lewandowska, and J. Holowiecki
Interferon {alpha} induces a good molecular response in a patient with chronic eosinophilic leukemia (CEL) carrying the JAK2V617F point mutation
Haematologica,
November 1, 2007;
92(11):
e118 - e119.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Reiter, D. Grimwade, and N. C.P. Cross
Diagnostic and therapeutic management of eosinophilia-associated chronic myeloproliferative disorders
Haematologica,
September 1, 2007;
92(9):
1153 - 1158.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Tefferi, J. Thiele, A. Orazi, H. M. Kvasnicka, T. Barbui, C. A. Hanson, G. Barosi, S. Verstovsek, G. Birgegard, R. Mesa, et al.
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel
Blood,
August 15, 2007;
110(4):
1092 - 1097.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. M. Vannucchi, E. Antonioli, P. Guglielmelli, A. Rambaldi, G. Barosi, R. Marchioli, R. M. Marfisi, G. Finazzi, V. Guerini, F. Fabris, et al.
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia
Blood,
August 1, 2007;
110(3):
840 - 846.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M.-P. Wautier, W. El Nemer, P. Gane, J.-D. Rain, J.-P. Cartron, Y. Colin, C. Le Van Kim, and J.-L. Wautier
Increased adhesion to endothelial cells of erythrocytes from patients with polycythemia vera is mediated by laminin {alpha}5 chain and Lu/BCAM
Blood,
August 1, 2007;
110(3):
894 - 901.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. J. Walne, T. Vulliamy, A. Marrone, R. Beswick, M. Kirwan, Y. Masunari, F.-h. Al-Qurashi, M. Aljurf, and I. Dokal
Genetic heterogeneity in autosomal recessive dyskeratosis congenita with one subtype due to mutations in the telomerase-associated protein NOP10
Hum. Mol. Genet.,
July 1, 2007;
16(13):
1619 - 1629.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Finazzi and T. Barbui
How I treat patients with polycythemia vera
Blood,
June 15, 2007;
109(12):
5104 - 5111.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Tefferi and A. Pardanani
Evaluation of 'Increased' Hemoglobin in the JAK2 Mutations Era: A Diagnostic Algorithm Based on Genetic Tests
Mayo Clin. Proc.,
May 1, 2007;
82(5):
599 - 604.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Hammond, K. Shaw, B. Carnley, S. P'ng, I. James, and R. Herrmann
Quantitative Determination of JAK2 V617F by TaqMan: An Absolute Measure of Averaged Copies per Cell That May Be Associated with the Different Types of Myeloproliferative Disorders
J. Mol. Diagn.,
April 1, 2007;
9(2):
242 - 248.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Q. Chen, P. Lu, A. V. Jones, N. C.P. Cross, R. T. Silver, and Y. L. Wang
Amplification Refractory Mutation System, a Highly Sensitive and Simple Polymerase Chain Reaction Assay, for the Detection of JAK2 V617F Mutation in Chronic Myeloproliferative Disorders
J. Mol. Diagn.,
April 1, 2007;
9(2):
272 - 276.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Teofili, F. Giona, M. Martini, T. Cenci, F. Guidi, L. Torti, G. Palumbo, A. Amendola, R. Foa, and L. M. Larocca
Markers of Myeloproliferative Diseases in Childhood Polycythemia Vera and Essential Thrombocythemia
J. Clin. Oncol.,
March 20, 2007;
25(9):
1048 - 1053.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Li, M. Xu, S. Xing, W. T. Ho, T. Ishii, Q. Li, X. Fu, and Z. J. Zhao
Erlotinib Effectively Inhibits JAK2V617F Activity and Polycythemia Vera Cell Growth
J. Biol. Chem.,
February 9, 2007;
282(6):
3428 - 3432.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. C. Wolstencroft, K. Hanlon, L. W. Harries, G. R. Standen, A. Sternberg, and S. Ellard
Development of a Quantitative Real-Time Polymerase Chain Reaction Assay for the Detection of the JAK2 V617F Mutation
J. Mol. Diagn.,
February 1, 2007;
9(1):
42 - 46.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Tefferi
JAK2 Mutations in Polycythemia Vera -- Molecular Mechanisms and Clinical Applications
N. Engl. J. Med.,
February 1, 2007;
356(5):
444 - 445.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. M. Scott, W. Tong, R. L. Levine, M. A. Scott, P. A. Beer, M. R. Stratton, P. A. Futreal, W. N. Erber, M. F. McMullin, C. N. Harrison, et al.
JAK2 Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis
N. Engl. J. Med.,
February 1, 2007;
356(5):
459 - 468.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Walz, G. Metzgeroth, C. Haferlach, A. Schmitt-Graeff, A. Fabarius, V. Hagen, O. Prummer, S. Rauh, R. Hehlmann, A. Hochhaus, et al.
Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor {beta} gene
Haematologica,
February 1, 2007;
92(2):
163 - 169.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. E. Gale, A. J.R. Allen, M. J. Nash, and D. C. Linch
Long-term serial analysis of X-chromosome inactivation patterns and JAK2 V617F mutant levels in patients with essential thrombocythemia show that minor mutant-positive clones can remain stable for many years
Blood,
February 1, 2007;
109(3):
1241 - 1243.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. L. Andersen, C. Wiuf, M. Kruhoffer, M. Korsgaard, S. Laurberg, and T. F. Orntoft
Frequent occurrence of uniparental disomy in colorectal cancer
Carcinogenesis,
January 1, 2007;
28(1):
38 - 48.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Brakensiek, L. U. Wingen, F. Langer, H. Kreipe, and U. Lehmann
Quantitative High-Resolution CpG Island Mapping with PyrosequencingTM Reveals Disease-Specific Methylation Patterns of the CDKN2B Gene in Myelodysplastic Syndrome and Myeloid Leukemia
Clin. Chem.,
January 1, 2007;
53(1):
17 - 23.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Delhommeau, S. Dupont, C. Tonetti, A. Masse, I. Godin, J.-P. L. Couedic, N. Debili, P. Saulnier, N. Casadevall, W. Vainchenker, et al.
Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis
Blood,
January 1, 2007;
109(1):
71 - 77.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Xu, Q. Zhang, J. Luo, S. Xing, Q. Li, S. B. Krantz, X. Fu, and Z. J. Zhao
JAK2V617F: prevalence in a large Chinese hospital population
Blood,
January 1, 2007;
109(1):
339 - 342.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. J. Campbell and A. R. Green
The Myeloproliferative Disorders
N. Engl. J. Med.,
December 7, 2006;
355(23):
2452 - 2466.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. G.P. Bumm, C. Elsea, A. S. Corbin, M. Loriaux, D. Sherbenou, L. Wood, J. Deininger, R. T. Silver, B. J. Druker, and M. W.N. Deininger
Characterization of Murine JAK2V617F-Positive Myeloproliferative Disease
Cancer Res.,
December 1, 2006;
66(23):
11156 - 11165.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. R. Moliterno, D. M. Williams, O. Rogers, and J. L. Spivak
Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression
Blood,
December 1, 2006;
108(12):
3913 - 3915.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. J. Campbell, E. J. Baxter, P. A. Beer, L. M. Scott, A. J. Bench, B. J. P. Huntly, W. N. Erber, R. Kusec, T. S. Larsen, S. Giraudier, et al.
Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation
Blood,
November 15, 2006;
108(10):
3548 - 3555.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Szpurka, R. Tiu, G. Murugesan, S. Aboudola, E. D. Hsi, K. S. Theil, M. A. Sekeres, and J. P. Maciejewski
Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation
Blood,
October 1, 2006;
108(7):
2173 - 2181.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. P. Steensma
JAK2 V617F in Myeloid Disorders: Molecular Diagnostic Techniques and Their Clinical Utility: A Paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology
J. Mol. Diagn.,
September 1, 2006;
8(4):
397 - 411.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Horn, M. Kremer, T. Dechow, W. M. Pfeifer, B. Geist, M. Perker, J. Duyster, L. Quintanilla-Martinez, and F. Fend
Detection of the Activating JAK2 V617F Mutation in Paraffin-Embedded Trephine Bone Marrow Biopsies of Patients with Chronic Myeloproliferative Diseases
J. Mol. Diagn.,
July 1, 2006;
8(3):
299 - 304.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Lay, R. Mariappan, J. Gotlib, L. Dietz, S. Sebastian, I. Schrijver, and J. L. Zehnder
Detection of the JAK2 V617F Mutation by LightCycler PCR and Probe Dissociation Analysis
J. Mol. Diagn.,
July 1, 2006;
8(3):
330 - 334.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Sidon, P. Heimann, F. Lambert, B. Dessars, V. Robin, and H. El Housni
Combined Locked Nucleic Acid and Molecular Beacon Technologies for Sensitive Detection of the JAK2V617F Somatic Single-Base Sequence Variant.
Clin. Chem.,
July 1, 2006;
52(7):
1436 - 1438.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Wernig, T. Mercher, R. Okabe, R. L. Levine, B. H. Lee, and D. G. Gilliland
Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model
Blood,
June 1, 2006;
107(11):
4274 - 4281.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. L. Levine, C. Belisle, M. Wadleigh, D. Zahrieh, S. Lee, P. Chagnon, D. G. Gilliland, and L. Busque
X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis
Blood,
May 15, 2006;
107(10):
4139 - 4141.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Walczak
Polycythemia vera erythroblasts: too tough to die
Blood,
May 1, 2006;
107(9):
3422 - 3423.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Zeuner, F. Pedini, M. Signore, G. Ruscio, C. Messina, A. Tafuri, G. Girelli, C. Peschle, and R. De Maria
Increased death receptor resistance and FLIPshort expression in polycythemia vera erythroid precursor cells
Blood,
May 1, 2006;
107(9):
3495 - 3502.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. V. Jones, R. T. Silver, K. Waghorn, C. Curtis, S. Kreil, K. Zoi, A. Hochhaus, D. Oscier, G. Metzgeroth, E. Lengfelder, et al.
Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha
Blood,
April 15, 2006;
107(8):
3339 - 3341.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Tefferi, M. A. Elliott, and A. Pardanani
Atypical Myeloproliferative Disorders: Diagnosis and Management
Mayo Clin. Proc.,
April 1, 2006;
81(4):
553 - 563.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. P. Steensma, A. Pardanani, W. S. Stevenson, R. Hoyt, H. Kiu, A. P. Grigg, J. Szer, S. Juneja, D. J. Hilton, W. S. Alexander, et al.
More on Myb in myelofibrosis: molecular analyses of MYB and EP300 in 55 patients with myeloproliferative disorders
Blood,
February 15, 2006;
107(4):
1733 - 1735.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. L. Levine and G. Wernig
Role of JAK-STAT Signaling in the Pathogenesis of Myeloproliferative Disorders
Hematology,
January 1, 2006;
2006(1):
233 - 239.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Tefferi
Classification, Diagnosis and Management of Myeloproliferative Disorders in the JAK2V617F Era
Hematology,
January 1, 2006;
2006(1):
240 - 245.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Tefferi
V617F "JAKs" up myeloproliferative signal
Blood,
November 15, 2005;
106(10):
3335 - 3336.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. L. Levine, M. Loriaux, B. J. P. Huntly, M. L. Loh, M. Beran, E. Stoffregen, R. Berger, J. J. Clark, S. G. Willis, K. T. Nguyen, et al.
The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia
Blood,
November 15, 2005;
106(10):
3377 - 3379.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Vainchenker and S. N. Constantinescu
A Unique Activating Mutation in JAK2 (V617F) Is at the Origin of Polycythemia Vera and Allows a New Classification of Myeloproliferative Diseases
Hematology,
January 1, 2005;
2005(1):
195 - 200.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|